Moleculin Announces Peer-Reviewed Analysis Finds No Cardiotoxicity with Annamycin at High Cumulative Doses
Moleculin announced a peer-reviewed pooled analysis showing no clinical or subclinical cardiotoxicity with Annamycin across 90 patients.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…